Article

Acuity improves with TTT, study says

Mountain View, CA—Patients with wet age-related macular degeneration (AMD) who were treated with a transpupillary thermotherapy (TTT) laser protocol showed a significant clinical benefit of improved vision versus those in a sham-treated control group, according to Iridex Corp.

Mountain View, CA-Patients with wet age-related macular degeneration (AMD) who were treated with a transpupillary thermotherapy (TTT) laser protocol showed a significant clinical benefit of improved vision versus those in a sham-treated control group, according to Iridex Corp.

In a subgroup of patients with baseline acuity of 20/100 or worse, 22% of treated eyes had improved vision by one or more lines compared with none of the eyes in the untreated control group, according to the company.

At 18 months, there was a 2-line benefit compared with sham-treated eyes. TTT-treated eyes lost an average of 2 lines of acuity, while sham-treated eyes lost 4 lines.

"This compares with no vision improvement for patients in the sham-treated control group," Dr. Reichel said. "These results support a role for TTT in the treatment of a significant fraction of patients with occult wet AMD worldwide."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
© 2025 MJH Life Sciences

All rights reserved.